Study evaluates the use of tirzepatide in overweight/obese adults with type 1 diabetes

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the use of tirzepatide in overweight/obese adults with type 1 diabetes.

Opinion | ‘If We Have a Thermonuclear War, All I Need Is a Scalpel’: What We Heard This Week

“If we have a thermonuclear war, all I need is a scalpel.” — Stavropoula Tjoumakaris, MD, of Thomas Jefferson University in Philadelphia, during an FDA

February 12, 2024

Research uncovers key therapeutic target for reversing accelerated atherosclerosis in diabetes

Diabetes accelerates the development of atherosclerosis, increasing the incidence of cardiovascular events.

February 29, 2024

Greenlane Q2 Revenue Declines to $19.6 Million

GREENLANE REPORTS Q2 2023 FISCAL RESULTS BOCA RATON, FL / August 14, 2023 / Greenlane Holdings, Inc. (“Greenlane” or the “Company”) (NASDAQ:GNLN), a premier global

August 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.